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1. Introduction 
Fragile X syndrome (FXS, OMIM #300624) is the most common form of inherited mental 
retardation. The real incidence of the syndrome is not known, but epidemiological studies 
indicate that it is responsible for mental retardation in 1 in 4,000-6,000 males and in 1 in 
7,000-10,000 females of European descendent (for review Hagerman, 2002). In a study 
performed in Catalonia it gave an incidence of 1:2,466 male and 1:8,333 females (Rife et al., 
2003). It is also important to highlight the high incidence of premutation carriers, 1 in 1,233 
males and 1 in 411 females (Rife et al., 2003). FXS is inherited as X-linked dominant trait, 
with a reduced penetrance (80% for males and 30% for females).  
In 1991 the responsible gene was identified by positional cloning and named the fragile X 
mental retardation-1 gene (FMR1) (Oberle et al., 1991; Verkerk et al., 1991; Yu et al., 1991). 
The FMR1 gene is located in the long arm of the X chromosome at Xq27.3, it expands 17 
exons, and 40 kb of genomic DNA. It transcribes an mRNA of 3.9 kb, and the translated 
protein is called fragile X mental retardation protein (FMRP). The lack of this protein, which 
plays an important role in synaptogenesis and synaptic plasticity (Basell & Warren, 2008), is 
the cause of the FXS.  
FXS is almost exclusively caused by a dynamic mutation, a CGG repeat expansion in the 5’ 
untranslated region of the FMR1 gene (Oberle et al., 1991; Verkerk et al., 1991; Yu et al., 1991). 
In a normal situation the number of CGG repeats is polymorphic with alleles between 6 to 
about 54, with the most common allele presenting 30 CGG repeats. In this situation the CpG 
island, which is located in the promoter of the gene acting as a switch depending on its 
methylation status, is unmethylated. Thus the gene is active, FMR1 is transcribed and 
translated. Repeats at this size remain stable upon transmission. A second class of alleles 
that overlaps with the upper range of the wild-type is those with ~40-55 CGGs. This range, 
known as the gray zone, no expands to full mutation but it is transmitted slightly unstable 
to subsequent generations with the possibility of creating a premutated allele. In the 
premutation, alleles range from 55 to about 200 CGG repeats. At this situation, the FMR1 
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gene is also transcribed as the CpG island is unmethylated. Therefore, premutated carriers 
have normal or lightly reduced synthesis of FMRP and they are asymptomatic for FXS. 
However, they have risk of having affected descendence since the number of CGG is 
unstable, and in each cellular division it can increase, and can be transmitted with a higher 
number of repeats to the next generation. Finally, when the CGG number is beyond 200 
repeats (known as full mutation), the CpG island is methylated, and as consequence, the 
gene is transcriptionally silenced, and no protein is translated. These individuals are always 
affected if they are males and in about 30% of females. 
In this chapter we review the clinical, molecular and neuroradiological aspects of FXTAS 
syndrome, a late-onset neuropsychiatric degenerative disorder that occurs predominantly in 
male carriers of the FMR1 premutation. Based on our experience we describe in detail the 
different aspects that characterize the syndrome as well as the new findings. 
2. Fragile X syndrome premutation and FXTAS identification 
The possibility of clinical involvement in carriers of premutation expansions (55 to 200 CGG 
repeats) of FMR1 gene was initially discounted, since carrier mothers of FXS children have a 
normal cognitive functioning (Bennetto et al., 2001; Reiss et al., 1993). Even though, and 
contrary to expectation, there are reported several subgroups of male and female 
premutation carriers displaying features consistent with the typical clinical spectrum of FXS. 
For instance, Riddle and co-workers (1998) and Hagerman (2002) described a group of 
premutation carriers with prominent ears and joint laxity; or with learning disabilities, 
attention deficit/hyperactivity disorder (ADHD), or difficulty with math (Riddle et al., 1998, 
reviewed in Hagerman & Hagerman 2004). In addition, some carriers have emotional 
problems, including anxiety, obsessional thinking, schizotypy, and/or depression 
(Hagerman et al., 2002; Rodriguez-Revenga et al., 2008a). Such findings were observed to be 
more likely to occur in carriers with a lowered FMRP levels and particularly in those carrier 
females with larger CGG expansions (>100 repeats) (Johnston et al., 2001). 
There are, however, two forms of clinical involvement among carriers of premutation 
alleles that are not consistent with the clinical spectrum of the FXS. These two disorders 
are the primary ovarian insuffiency (FXPOI) and the fragile X-associated tremor/ataxia 
syndrome (FXTAS). FXPOI, which refers to the cessation of menses before age 40, is seen 
in ~20% of female who carry permutation alleles. Therefore, the genetic counseling for 
premutated women has to include a fertility advice since delaying the reproduction may 
not be a good option.  
FXTAS, the second form of clinical involvement described among permutation carriers, was 
identified in 2001 by Hagerman and co-workers as a late-onset neurodegenerative disorder 
(Hagerman et al., 2001). It took more than 10 years after the FMR1 gene identification to 
recognize FXTAS as a FMR1 permutation associated phenotype. One explanation for this is 
that the movement disorder experienced by older carriers, who were thought to be clinically 
normal, was not associated with the FXS (a childhood disorder) affecting children. Mothers 
of FXS children, being seen in clinics, were often expressing concerns about their fathers 
(FMR1 premutation carriers) who were experiencing problems with hand tremor and 
unsteady gait. When Hagerman and co-workers evaluated these male carriers they found 
that they all have a common neurological profile, consisting of intention tremor and gait 
ataxia (reviewed in Hagerman & Hagerman 2004). Therefore, FXTAS was firstly identified 
among older male carriers of premutation alleles, including progressive action tremor and 
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ataxia with associated radiological findings (Hagerman & Hagerman 2004). However, to 
date FXTAS has also been described among premutated women although it has been 
suggested that it occurs less frequently and that the phenotype is milder with older age at 
onset (Hagerman et al., 2001; Jacquemont et al., 2004a). An explanation for this difference is 
the presence of a second normal allele and a random X-inactivation of the premutated one; 
however, there may be additional sex-specific effects that reduce penetrance among females 
(Hagerman & Hagerman, 2004). 
Not all FMR1 premutation carriers develop FXTAS and it remains unknown which 
carriers will do so and when. It has been estimated that at least one-third of all male 
carriers will develop a FXTAS syndrome, although the penetrance increases with age, 
exceeding 50% for men aged 70-90 years. Moreover, there is significant variability in the 
progression of neurological dysfunction (Hagerman & Hagerman 2004; Jacquemont et al., 
2004a, 2004b). In an attempt to provide an estimation of FXTAS penetrance among 
premutation carriers in Spanish FXS families, we evaluated 398 families among which 151 
were composed of at least three generations. Our results showed that signs of FXTAS 
were detected in 16.5% of female premutation carriers and in 45.5% of premutated males 
older than 50 years. Overall, the mean age and the mean of CGG repeat number for the 
FXTAS men group was of 72.05 ± 6.85 and 85 ± 21.5 (mean ± SD), respectively. Similarly it 
was of 75.8 years old ± 10.2 and 82 CGG repeats ± 18 (mean ± SD) for the FXTAS women 
group (Rodriguez-Revenga et al., 2009).  
The description and characterization of FXTAS syndrome is of great interest to the 
population, because the prevalence of FMR1 premutation in the general population is 
relatively high. Several studies have been performed in order to determine the real role of 
FXTAS in undiagnosed adult patients with movement disorders. The results obtained in 
European populations ranges from 0% to 4% (Brussino et al.,2005; Macpherson et al., 2003; 
Van Esch et al., 2005; Zuhlke et al., 2004). Our studies show an estimated FXTAS 
prevalence of 2% among patients presenting with ataxia or movement disorders of 
unknown etiology (Rodriguez-Revenga et al., 2007, 2008b). Although large studies are 
necessary to better define FXTAS prevalence in this kind of population, on the basis of 
premutation male frequency in general population, the prevalence of FXTAS has been 
estimated in ~1/3,000 males aged over 50 years of age (~1/10,000 males of all ages) 
(Hagerman & Hagerman, 2004).  
3. Clinical and cognitive overview  
FXTAS syndrome is a neurodegenerative disease that eventually appears in adult subjects 
who carry a CGG repeat length between 55 and 200 trinucleotides in the FMR1 gene of 
chromosome X (Jacquemont et al., 2007). These subjects are categorized as FMR1 
premutation carriers. As stated above, it was originally described in grandparents of 
children with FXS. Different specialized centres in diagnosing and attending children with 
FXS observed that their grandparents and uncles were more likely to develop, from 50 years 
onwards, a stereotyped clinical picture characterized by unsteadiness while walking and 
action tremor in both hands (Hagerman et al., 2001).  
Neurological examination of children’s relatives disclosed the presence of predominant 
intention tremor in hands and wide-base cerebellar ataxia. Both symptoms used to follow a 
progressive course, and were often accompanied by progressive cognitive and behavioral 
disturbances (Hagerman et al., 2001).  
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Clinical descriptions published in the past 10 years have demonstrated that FMR1 
premutation carriers are very prone to develop cerebellar dysfunction from the age of 50 
years. Seveirty of symptoms usually impairs gait and associates mild to moderate 
dysmetria, repeated falls, intention tremor, and speech difficulties. The combination of 
cerebellar dysfunction, cognitive impairment and the appearance of characteristic radiologic 
features in the brain MRI has been claimed to constitute a nosological entity that has been 
named Fragile X-associated Tremor/Ataxia syndrome (FXTAS).  
In the only study about the natural history of patients with FXTAS, this syndrome has been 
observed to represent a disabling condition impacting on motor daily activities, thinking, 
and social skills after 15 years of evolution (Jacquemont et al., 2003).  
Mean age of onset of FXTAS is 60 years. Mild intention tremor, affecting both hands,  
symmetrically, is usually the first symptom. Within the first 5 years, tremor becomes more 
apparent and some balance and speech problems develop. At this stage, balance problems 
are mild and are only noticed by patients as a feeling of unsteadiness while walking for long 
periods of time or when turning. Between 5 and 15 years from disease onset balance 
problems progress in severity and are usually the main complain, provoking repeated 
falling and limiting the ability to drive, walking autonomously in the streets, or using public 
transportation. At this stage, moreover, is when the first cognitive and behavioural 
disturbances appear.  After 15 years, autonomous walk is greatly impaired, and patients 
need the help of a walker or the supervision of another person. Finally, dysphagia and 
severe ataxia are associated with immobility and recurrent urinary and respiratory 
infections (Leehey et al., 2007). 
The penetrance of FXTAS is not well established. Penetrance increases with age, and it has 
been reported to range from 15% at 50 years of age to 75% at age 80 (Jacquemont et al., 
2004b). 
Being a relatively newly described condition, the clinical spectrum of the disease has 
expanded in the past years. As in other diseases, such as Parkinson’s disease, FXTAS was 
initially conceived as a predominant motor disease. New data have evidenced that many 
clinically relevant cognitive and behavioural disturbances may also develop in FXTAS 
patients. Also, while FXTAS was originally described in males, the number of women 
developing FXTAS symptoms has increased exponentially in the past five years. Women 
have been reported to develop the same motor, cognitive and behavioural problems than 
males, although women are more likely to develop a milder form of the disease (Coffey et 
al., 2008). Nevertheless, cognitive dysfunction severe enough to accomplish criteria for 
dementia has been reported in FXTAS women with inactivation of the healthy X-
chromosome (Rodriguez-Revenga et al., 2010). 
Cognitive impairment in FXTAS is characterized by recent episodic memory problems, 
difficulties in sustained attention, and other executive problems such as organizing new 
material and inhibiting automatic responses. In males, initially mild cognitive problems can 
accomplish criteria for dementia after 5 to 10 years of evolution (Grisby et al., 2007). 
Extension of the neurodegenerative process to prefrontal and temporal structures seems to 
account for the progression of cognitive defects in FXTAS patients (Seritan et al., 2008). 
While balance problems and tremor seem to be the consequence of the progressive 
degeneration of middle cerebellar peduncles and associated cerebellar structures, both 
cognitive and behavioural problems in FXTAS are associated with diffuse cortical and 
white-matter subcortical degeneration (Hashimoto et al., 2011).  
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The dysexecutive problems of FXTAS patients affect different prefrontal dominions. 
Cognitive tasks dependent on the dorsolateral prefrontal cortex are affected since the early 
stages of the disease. Problems in working memory, set-shifting and mental flexibility have 
been described in patients with mild ataxia and tremor (Grisby et al., 2007). Later in the 
disease, cognitive alterations more dependent on the medial prefrontal cortex, such as 
difficulties in inhibiting automatic responses, arise. Response inhibition in go-no go tasks, 
inability to perform Luria’s promotor series, and signs of environmental dependency were 
seen not only to limit the ability of FXTAS’ patients to cope with cognitive strategies in the 
daily life, but also accounted for the behavioral disorders of the disease (Moore et al., 2004a). 
Memory problems develop due to both prefrontal and medial temporal dysfunction. 
Numerous eosinophylic inclusions have been observed bilaterally in the hippocampus and 
the entorrhinal cortex. Progressive deterioration and atrophy of medial temporal lobe 
structures explains the progressive nature of temporal disorientation and both verbal and 
visual recent episodic memory. (Grisby et al., 2008). In comparison with Alzheimer’s disease, 
FXTAS patients show a higher impairment in dysexecutive tasks and less memory 
impairment, and in comparison with Parkinson’s disease, visuospatial skills seem to be 
more preserved. In addition, compared to both Parkinson’s disease and dementia with 
Lewy bodies, FXTAS patients are less likely to manifest visual hallucinations and psychosis 
(Grisby et al., 2008). 
Neuropsychiatric disturbances in FXTAS are characterized by a change in premorbid 
personality. Patients with FXTAS, as in frontotemporal dementia, may develop irritability, 
psychomotor agitation, a tendency to selfishness, blunted emotions, apathy, and sometimes 
even social and personal disinhibition. Similarities with frontotemporal dementia correlate 
with the evidence of predominant medial prefrontal and anteromedial temporal atrophy in 
neuroimaging studies (Bacalman et al., 2006). 
In summary, fronto-temporal cognitive and behavioral disturbances seem to characterize 
FXTAS patients. Frontal cognitive symptoms are present in early stages and progress 
through disease evolution, medial prefrontal behavioral disturbances appear in the middle 
stages and progress also in severity, and finally, from medium to late FXTAS stages, 
temporal cognitive symptoms impair even more global cognitive function and lead to 
dementia. A better delineation of each one of these components would help to refine the 
progression of cognitive and behavioural symptoms in different FXTAS subgroups (age, 
gender, etc…). 
Other neurological disturbances described in FXTAS patients are the development of rigid-
akinetic parkinsonism with predominant axial involvement (35%), unilateral resting tremor 
(10%), peripheral neuropathy (30%), dysautonomia (40-50%; urinary urgency, erectile 
dysfunction, orthostatic hypotension), nistagmus (10%), and hyporreflexia (10%). 
In some patients, postural and intention tremor may present in isolation, making the 
diagnosis of essential tremor very likely. Reported cases stress the importance of 
considering the diagnosis of FXTAS in patients diagnosed of essential tremor who develop 
ataxia or with a family history of mental retardation (Leehey et al., 2003). Other patients 
present with isolated and progressive adult-onset ataxia. Currently, genetic testing for 
FXTAS must be considered in any patient with ataxia developing after the age of 50. The 
screening of FXTAS in a prospective series of patients with multiple system atrophy showed 
that 4% of patients with an initial diagnosis of multiple system atrophy of the cerebellar type 
were actually FMR1 premutation carriers (Kamm et al., 2005). Taking into account the 
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consequences of a diagnosis of FXTAS on genetic counselling, FXTAS should be categorized 
as a new kind of spinocerebellar ataxia (Milà et al., 2009).  
4. Molecular genetics overview 
FXTAS is an allelic disorder to the FXS, and therefore should be considered as a distinct 
neurodegenerative disorder. In fact, the molecular mechanism leading to FXTAS is distinct 
from the FMR1 silencing mechanism and/or a deficit in FMRP operating in FXS. In 
premutated patients the FMR1 gene is rarely silenced and FMRP levels are generally normal 
or only slightly lowered (Hagerman & Hagerman, 2004) (Fig.1a). The only known molecular 
abnormality among premutation carriers is the presence of markedly elevated levels (~2-8 
fold) of FMR1 mRNA (Fig.1b).  
 
  
Fig. 1. a) Schematic representation of FMRP levels detected in A: FXS affected individuals, 
N:  individuals with a normal CGG repeat number; NTM: FMR1 premutation male carriers 
and Pre: FMR1 premutation  female carriers. B) Schematic representation of FMR1 mRNA 
levels detected in A: FXS affected individuals, N:  individuals with a normal CGG repeat 
number; NTM: FMR1 premutation male carriers and Pre: FMR1 premutation  female 
carriers. 
The increased transcriptional activity of the FMR1 gene seems to be positively correlated 
with the size of the CGG repeat. That is, CGG repeats in the upper range (100-200 CGG) 
result in average 5-8 fold elevation, whereas CGGs in the lower range (50-100 CGG) result in 
an average 2-fold elevation (Kenson et al., 2001; Oostra & Willemsen, 2003; Tassone et al., 
2000a, 2000b). Although the precise mechanism for this overexpression is unknown, several 
possible mechanisms have been postulated. A feedback mechanism suggests that the cell 
attempts to compensate for reduced levels of FMRP by increasing the amount of available 
FMR1 transcript (reviewed in Galloway & Nelson, 2009; Tassone & Hagerman, 2003). 
Alternatively, it is likely that the increasing length of the CGG repeat near the FMR1 
promoter proportionally opens the chromatin, allowing more ready access to transcription 
factors (Tan el al., 2009). The presence of these elevated levels of abnormal (expanded CGG 
repeat) FMR1 mRNA led to propose an RNA “toxic gain-of-function” model for FXTAS, in 
which the mRNA itself, with the abnormal CGG repeat tract, is causative of the neurological 
a 
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disorder (Greco et al., 2002: Hagerman & Hagerman, 2004; Hagerman et al., 2001: 
Jacquemont et al., 2003). Although several evidences support the RNA-based mechanism, 
the precise form of how the CGG-repeat RNA is responisble for FXTAS pathogenesis is not 
yet resolved (Garcia-Arocena & Hagerman, 2010) The same RNA “toxic gain-of-function” 
mechanism has been proposed for myotonic dystrophy (DM1 and DM2), in which either the 
expanded repeat tract of CUG in DM1 or CCUG in DM2 sequestered CUG-binding proteins 
that disrupts mRNA processing of other genes or transport of other mRNAs (Mankodi & 
Thornton, 2002). In fact, this model has been demonstrated for DM1 by placing an expanded 
CTG tract in 3’ UTR region of the DMPK mRNA in a transgenic mouse (Mankodi et al., 
2000). A part from this finding, FXTAS and myotonic dystrophy have another important 
similarity that supports the RNA gain-of-function mechanism. Both disorders show nuclear 
inclusions produced as a result of the binding proteins sequestered by the respectively 
mRNA, with a cytotoxic effect that lead to cell death. In a study performed by Greco and co-
worker (2002) eosinophilic intranucelear inclusions in neurons and astrocytes throughout 
the cortex and in deep cerebellar nuclei of FXTAS post-mortem samples were reported. 
Furthermore, in a subsequent study, there is described a highly significant association 
between CGG length and both the number of inclusions and the age of death, which 
correlates with the progressive character of the disease (Greco et al., 2006). The intranuclear 
inclusions associated with FXTAS have characteristic features different than those found in 
tauopathies (e.g., Pick disease), synucleinopathies (e.g., Lewy body dementias and 
Parkinson disease) or polyglutamine disorders (SCAs). It is important to note that, unlike 
the polyglutamine disorders, there is no known structurally abnormal protein with FXTAS 
(reviewed in Galloway & Nelson, 2009; Iwahashi et al., 2006). Taken together, these facts 
define FXTAS as a new class of inclusion disorder. 
In order to test the RNA gain-of-function hypothesis for FXTAS, a “knock-in” mouse model 
has been generated in which the endogenous mouse CGG repeat was replaced by a human 
CGG tract carrying 98 CGGs (Bontekoe et al., 2001; reviewed in Oostra & Willemsen, 2009). 
Further studies of the brain of these expanded-repeat mice (at 20-72 weeks) evidenced 
elevated Fmr1 mRNA levels and ubiquitin-positive intranuclear inclusions (Willemsen et al., 
2003). An increase was also observed in both the number and the size of the inclusions in 
specific brain region during the course of life (Oostra & Willemsen, 2003). The presence of 
inclusions in this mouse, that has normal levels of FMRP, provides evidences against a 
protein-deficiency model for FXTAS, and supports a direct role of the Fmr1 gene, by either 
CGG expansion per se or by elevated Fmr1 mRNA levels, in the pathology.  
There are several other animal and cell-based studies that provide evidence of direct RNA 
toxicity (Galloway & Nelson, 2010; reviewed in Garcia-Arocena & Hagerman, 2010). Most of 
these studies have demostrated a sequestartion of several candidates CGG-repeat binding 
proteins from their normal function. Remarkably, they have also demonstrated at least 
partial rescue of the wild-type phenotype by overexpressing the sequestered protein. The 
number of candidate proteins for sequestration has been lately increased and surprisingly, it 
has also been shown that inclusions are dynamic structures that expanded over time, 
resulting in giant inclusions (Sellier et al., 2010). Continuous enlargements of CGG RNA 
aggregates suggest that these repeats may constantly recruit proteins, implying a founding 
RNA-protein interaction event that would subsequently trap other proteins through indirect 
RNA-protein or protein-protein interactions (Sellier et al., 2010). The protein components of 
FXTAS inclusions fell into eight major functional categories, including: histone family; 
intermediate filament; microtubule; myelin-associated proteins; RNA-binding proteins; 
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stress-related proteins; chaperones and ubiquitin-proteasome-related proteins (reviewed 
Galloway & Nelson, 2010).  
Interestingly, an antisense transcript, ASFMR1, has recently been identified to overlap the 
CGG repeat region of the FMR1 gene (Ladd et al., 2007). Similar to FMR1, the ASFMR1 
transcript is silenced in full mutation individuals and overexpressed in permutation carriers. 
However, whether ASFMR1 contributes to the pathogenesis of either FXTAS or FXS remains 
to be determined (Tan et al., 2009). 
5. Neuroimaging findings – Conventional MRI strenghts and limitations 
FXTAS was originally described in men, older than 50 years of age, having a typical clinical 
picture of progressive intention tremor, and cerebellar ataxia (Hagerman et al 2001). 
Magnetic resonance imaging (MRI) of the brain was obtained in these patients searching for 
specific features, and the finding of hyperintensities in the cerebellar white matter and 
middle cerebellar peduncles on T2-weighted images was reported as a characteristic feature 
and called the “MCP sign” (Fig. 2a), as it was seen in nearly all FXTAS-premutated carriers, 
and not in controls (Brunberg et al., 2002). Other typical MR features described originally in 
patients with FXTAS included cerebellar, pontine, and cerebral atrophy, as well as white 
matter hyperintensities (Fig. 2 b-d) (Brunberg et al., 2002).  
 
a b
c d
 
Fig. 2. MR images showing characteristic findings in FXTAS. 1a. Axial FLAIR- MCP sign 
(middle cerebellar peduncle hyperintensities); 1b. Axial T1- Cerebellar and pontine atrophy; 
1c. Coronal T1- Cerebral atrophy; 1d. Axial FLAIR- Hyperintensities in the cerebral white 
matter.  
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Thus, characteristic findings described on conventional MRI in patients with FXTAS, were 
classified into two categories -major and minor criteria-, and proposed, together with 
clinical findings, as diagnostic criteria for FXTAS (Jacquemont et al., 2003). Major criteria 
included the MCP sign, as well as white matter and brainstem hyperintensities. Cerebellar 
and brain atrophy were proposed as minor criteria (Jacquemont et al., 2003) (Table 1). 
 
Examination and Degree Observation 
Radiological:  
Major MRI white matter lesions in MCPs and or brain stem 
Minor MRI white matter lesions in cerebral white matter 
Minor Moderate-to-severe generalized atrophy 
Clinical:  
Major Intention tremor 
Major Gait ataxia 
Minor Parkinsonism 
Minor Moderate-to-severe short-term memory deficiency 
Minor Executive function deficit 
Inclusion criterion: CGG repeat number between 55 and 200. 
Note. Data described by Jacquemont et al. 2003. 
Table 1. Clinical Criteria for FXTAS. The diagnostic categories described by Jaquemont et al. 
2003 are as follows: 
Definite (1 major radiological sign plus 1 major clinical symptom) 
Probable (1 major radiological sign plus 1 minor clinical symptom or two major clinical 
symptoms)  
Possible (1 minor radiological sign plus 1 major clinical symptom)  
Early neuropathological, postmortem studies of the brain of patients with FXTAS revealed 
intranuclear inclusions in neurons and astrocytes throughout the cortex and in deep 
cerebellar nuclei, but not in Purkinje cells of the cerebellum (Greco et al., 2002). Further 
evidence has shown that there is significant cerebral and cerebellar white matter disease, 
associated astrocytic pathology in the cerebral white matter, and intranuclear inclusions in 
both brain and spinal cord (Greco et al., 2006). Additionally, there seems to be an association 
between the number of CGG repeats and the number of intranuclear inclusions in neurons 
and astrocytes, so that CGG repeat has been suggested as a predictor for clinical and 
neuropathological involvement (Greco et al., 2006). Unfortunately, there is no 
histopathological evidence from brains of premutated, non-FXTAS subjects, who died 
because of an unrelated condition, being either asymptomatic neurologically, or little 
symptomatic. This evidence would certainly add in the understanding of the pathogenetic 
processes underlying glial and neuronal damage, and eventual neurological dysfunction. 
Brain banks and collaborative actions may represent a good opportunity in this regard. 
Penetrance of FXTAS among premutation carriers has been studied, and reported to be 
relevant, mainly in men (Jacquemont et al., 2004). As premutation carriers are relatively 
common in the general population, it has been proposed that older men with ataxia and 
intention tremor should be screened for the FMR1 mutation (Jacquemont 2004). Using the 
previously described criteria for FXTAS (Jacquemont et al., 2003), a study among adult 
Spanish patients with ataxia, revealed an estimated FXTAS prevalence varying between 
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1.15% for males, and 3% for females (Rodriguez-Revenga et al., 2007). Similarly, a frequency 
of 1.6% of patients with FXTAS has been reported among adult patients with movement 
disorders who tested negative for the Huntington gene (Rodriguez-Revenga et al., 2008b). 
The importance of neuroradiological findings that could be used as an additional screening 
tool for FXTAS is demonstrated by these studies.  
In this regard, the MCP sign, which was originally proposed to be a characteristic and 
specific feature for FXTAS, that could be used for screening purposes, has been also 
reported in patients with other forms of adult-onset cerebellar ataxia, thus lacking specificity 
for FXTAS (Okamoto et al., 2003). Patients with atypical parkinsonism, and particularly 
those having a clinical picture including dysautonomia, and ataxia -a condition currently 
known as the cerebellar form of Multiple System Atrophy (MSA)-, may show the MCP sign 
on MRI, so that middle cerebellar peduncles hyperintensities in a patient with parkinsonism 
should be regarded as a non-specific finding, which can be seen in FXTAS, but also in MSA 
(Kamm  et al., 2005). Additionally, the sensitivity of the MCP sign may be less than 
previously thought, as the frequency of the MCP sign among women with FXTAS seems to 
be less (Hagerman et al., 2004), and its presence among premutated men with subtle 
neurological, psychiatric, or cognitive dysfunction remains unknown.  
As more evidence among FMR1 premutation carriers developing neurological features, and 
particularly parkinsonism, is being gained, the spectrum and variability of MRI features 
becomes broader. Also, the severity of disease, which may relate to CGG repeat number, or 
other unknown factors, may influence the presence and magnitude of MRI findings. In this 
context, a correlation between CGG repeat length and reductions in IQ and cerebellar 
volume, and increased ventricular volume and whole-brain white matter hyperintensities, 
have been reported in FMR1 premutation carriers (Cohen et al.,  2006). It may well then be 
the case, that patients with a longer duration of neurological disturbances, or a greater 
severity, are those showing the so-known “typical MRI findings” of FXTAS. In this regard, 
more evidence is needed among younger premutated patients. Additionally, premutated 
women and women with FXTAS seem to have a different phenotype (Berry et al., 2004; 
Hagerman et al., 2004; Hessl et al., 2005), so that the frequency and relevance of MRI findings 
in women may be different from that in men. In this regard, less pronounced reductions in 
cerebellar volume and a lower incidence of the MCP sign has been reported in women with 
FXTAS compared to men (Adams et al., 2007). Also, an absence of significant associations 
between reduced cerebellar volumes and increased FXTAS severity, and increased length of 
the CGG repeat expansion was reported in women, differently from men having FXTAS 
(Adams et al., 2007).   
Conventional MRI, as including T1- and T2- weighted MR images, suffers from several 
limitations as a tool to investigate patients with a neurodevelopmental disorder that develop 
a neurodegenerative process later in life, as happens in the FMR1 premutation/FXTAS 
condition. Today, with the advent of high field strength MRI, and stronger gradients, there 
are more specific sequences such as susceptibility- or gradient-echo-weighted MR-images, 
which can provide more specific assessment of mechanisms underlying neuronal 
degeneration, such as iron deposition. Iron deposition is seen with normal aging in specific 
brain structures. Up to date, increased and/or iron deposition in certain brain structures has 
not been demonstrated among FXTAS patients, to the best of our knowledge, but this may 
only be a question of time or of the cohorts being studied. 
Also, recently FLAIR imaging has somehow substituted T2-weighted imaging for the 
assessment of white matter and brainstem T2- signal changes. Findings on FLAIR images 
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may not be exactly the same as seen on T2-weighted images, and thus, more evidence is 
needed with these more recent techniques. Finally, Arterial Spin Labeling, a non-invasive 
MRI method that allows detection of specific perfusion patterns of involvement linked to 
brain metabolism, is currently being applied to several neurodegenerative brain conditions, 
and may also be useful in the context of FMR1 premutation/FXTAS. 
6. Advances in neuroimaging in FXTAS and future needs  
The advancing field of Neuroradiology, and particularly of MRI, has provided insight in 
neurodegenerative conditions. Typical MRI findings have been described, that allow prompt 
and more precise characterization of many conditions, such as FXTAS. Additionally, MRI has 
provided non-invasive markers of disease, which may be potentially useful in early and 
differential diagnosis, in prognosis, and eventually in therapeutic response. This is the case for 
triplet expansion, genetic conditions, such as Huntington´s disease (HD), which offers some 
similarities to FXTAS. Originally, conventional MRI was used and typical MRI findings were 
described in HD, but recently, more sophisticated imaging methods, such as MR-
Spectroscopy, have been applied not only to patients with HD, but also to asymptomatic 
carriers, searching for markers for early diagnosis and conversion to disease. In this regard, 
metabolic (Gomez-Anson et al., 2007) and structural (Gomez-Anson et al., 2009) MR-alterations 
in the prefrontal regions of asymptomatic HD carriers have been recently described, linked to 
neuropsychological dysfunction, and proposed as early markers for disease, related to 
underlying pathology. Knowledge in field of FMR1 premutation carriers, who will eventually 
develop FXTAS, may follow a similar course. Although until now, mainly conventional MRI 
features have been described, there is growing evidence from more sophisticated MR 
techniques, which has and will continue adding knowledge in the field.   
Advances in Neuroimaging in FMR1 premutation/FXTAS may, perhaps, come from two 
distinct contributions. Firstly, more recent developments in MR are being applied to these 
patients. This is particularly the case of functional MR techniques, which not only provide 
information about structural brain changes in these patients, but also of brain functioning. As 
an example, MR-Spectroscopy (MRS) is a technique which allows studying non-invasively 
brain metabolism in vivo. Metabolic information can be linked to cellular pools, thus to 
histopathological changes, and to neuropsychological and clinical features. There is very little 
evidence about MRS in FXTAS. However, MRS changes indicating neuronal loss/dysfunction 
have been described in the pons of patients with FXTAS having the typical MCP sign on 
conventional imaging (Ginestroni et al., 2007). More recent evidence has shown altered 
metabolism on MRS in the middle cerebellar peduncles of patients with FMR1 premutation, 
which may be more marked in FXTAS (Gomez-Anson et al., abstract 2007). These findings 
indicate a potential usefulness of MRS, adding in differential diagnosis of patients with ataxias, 
and being able, perhaps, to identify those patients that will develop FXTAS. However, more 
longitudinal evidence and larger cohorts of carriers and patients from multicentric studies are 
needed in this regard. Functional MRI may also prove to be useful in the field of, as it has been 
recently demonstrated that there is altered prefrontal cortex activity underlying executive and 
memory deficits in permutated carriers and patients (Hashimoto et al., 2011). 
Secondly, contributions from more sophisticated postprocessing tools will certainly add 
during the near future in the field. In this context, assessment and quantification of volume 
changes in the brain is now feasible non-invasively using MRI and volumetric techniques. 
One of these techniques, the Voxel Based Morphometry method (VBM) allows 
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determination of focal changes of grey and white matter density in the brain on MRI 
(Ashburner et al., 2000). However, the evidence of volumetric studies in FXTAS and 
premutation carriers is scarce (Gomez-Anson et al., 2007; Hashimoto et al., 2011; Moore et al., 
2004b). Automated postprocessing tools are also being currently applied to study regional 
changes of volume in the brain, which may be specific to a condition, and related to certain 
cognitive tasks. This is the case of the hippocampus and memory impairment, which are 
relevant in Alzheimer´s disease, for example (Sanchez-Benavides et al., 2010). Evidence of 
the application of these tools to research in the FXTAS condition is still lacking. 
The potential usefulness of neuroimaging in providing insight in FXTAS becomes more 
evident as cognitive decline in FXTAS is resulting in an important field of research. As the 
phenotypic spectrum has expanded among FMR1 premutated carriers, and FXTAS patients, 
psychiatric and cognitive disturbances are increasingly being recognized as relevant features    
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Fig. 3. Magnetic resonance imaging findings of two female patients with dementia and 
FXTAS. A) Coronal T1-weighted, 3D MPRAGE MR image of patient 1 shows asymmetrical 
frontal, and bilateral, symmetrical, medial temporal atrophy. B) Axial 3D FLAIR of patient 1 
shows marked hyperintensities in the cerebral white matter. C) Coronal T1-weighted, 3D 
MPRAGE MR image of patient 2 shows moderate cerebral atrophy involving the frontal 
lobes, while the medial temporal lobes appeared normal.; K) Axial 3D FLAIR of patient 2 
shows no marked HI in the white matter. 
www.intechopen.com
 
Neuroimaging in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) 
 
435 
(Sevin et al., 2009). Cognitive decline in FXTAS usually occurs in men, after a long duration 
of extrapyramidal disturbances, but it may also occur in women. Typically in men, a clinical 
picture similar distinct from Alzheimer´s disease (Seritan et al.,  2008), and more similar to 
patients with fronto-temporal lobar degeneration occurs (FTLD) (Burgeois et al., 2009). 
Although there is little evidence from MRI in these patients, particularly in women (Al Hinti 
et al.,  2007; Karmon et al., 2008), more recently, two cases of mother-to-daughter 
transmission were reported (Rodriguez-Revenga et al., 2010). In these two female patients 
with FXTAS and dementia, a radiological pattern of brain atrophy resembling that of 
patients with FTLD, was described. However, radiological heterogeneity may be large in  
this condition, as shown by the fact that prominent white matter hyperintensities were only 
seen in one case, as had been previously described (Al Hinti et al.,  2007; Karmon et al., 2008), 
the second case lacking these, as well as hippocampal atrophy (Fig. 3). 
There is very recent evidence about the use of VBM for studying the brain changes of 
FMR1 premutated carriers, with and without FXTAS, and their correlation to 
neuropsychology (Hashimoto et al., 2011). In this study, patients with FXTAS 
demonstrated a distinct pattern of grey matter volume loss, involving multiple cortical 
and subcortical regions. This included different parts of the cerebellum, as well as of the 
medial surface of the brain, including the dorsomedial prefrontal cortex, anterior 
cingulate and precuneus. Additional volume loss was seen in the lateral prefrontal cortex, 
orbitofrontal cortex, amygdala, and insula. More interestingly, there were significant 
correlations between grey matter loss in different brain regions, behavioral scales, and 
CGG repeats (Hashimoto et al., 2011). 
7. Conclusion 
FXTAS is a relatively new disorders that is currently regarded as a late-onset 
neurodegenerative disorder; however, the underlying pathogenic process may begin very 
early in life. It is essential to fathom the molecular mechanism of FXTAS and to increase our 
knowledge of disease pathology in order to understand of FXTAS disease progression. 
Although the RNA gain-of-function hypothesis for FXTAS is well accepted, further analysis 
of the pathogenic effect of the expanded CGG-repeat FMR1 mRNA are still required. A 
better understanding of the molecular basis of FXTAS should shed light on therapeutic 
approaches that will combat neurodegeneration and improve cognitive and motor 
performance. Furthermore, it can also help unraveling common mechanisms in other 
neurodegenerative diseaser which will bring hope to treatments more effective and specific 
to the underlying dysfunction.  
MRI findings in FXTAS patients classically include middle cerebellar and white matter 
hyperintensities, as well as cerebellar, pontine and brain atrophy. Neuroimaging, and 
particularly MR techniques, offer an excellent opportunity to gain insight into the FXTAS 
condition. In vivo biomarkers may be identified non-invasively, which may be potentially 
useful in improving recognition, and early characterization of patients with FXTAS, so that 
treatment strategies can be developed and applied. 
As the prevalence of premutated alleles is relatively high in general population, FXTAS may 
represent one of the more common monogenic causes of tremor, ataxia, and dementia. For 
this reason, it is probably that many carriers with FXTAS are being seen by a clinical 
www.intechopen.com
 
Neuroimaging – Clinical Applications 
 
436 
specialist without awareness of the underlying genetic basis for the symptoms. The early 
diagnosis of those patients not only benefits themselves but also the rest of the family that 
should be advised for the FXS.  
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